Literature DB >> 29218504

Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.

Joanna L Elson1,2, Rafael Kochaj3, Richard Reynolds4, Ilse S Pienaar5,6.   

Abstract

Parkinson's disease (PD) is conventionally seen as resulting from single-system neurodegeneration affecting nigrostriatal dopaminergic neurons. However, accumulating evidence indicates multi-system degeneration and neurotransmitter deficiencies, including cholinergic neurons which degenerate in a brainstem nucleus, the pedunculopontine nucleus (PPN), resulting in motor and cognitive impairments. The neuropeptide galanin can inhibit cholinergic transmission, while being upregulated in degenerating brain regions associated with cognitive decline. Here we determined the temporal-spatial profile of progressive expression of endogenous galanin within degenerating cholinergic neurons, across the rostro-caudal axis of the PPN, by utilizing the lactacystin-induced rat model of PD. First, we show progressive neuronal death affecting nigral dopaminergic and PPN cholinergic neurons, reflecting that seen in PD patients, to facilitate use of this model for assessing the therapeutic potential of bioactive peptides. Next, stereological analyses of the lesioned brain hemisphere found that the number of PPN cholinergic neurons expressing galanin increased by 11%, compared to sham-lesioned controls, and increasing by a further 5% as the neurodegenerative process evolved. Galanin upregulation within cholinergic PPN neurons was most prevalent closest to the intra-nigral lesion site, suggesting that galanin upregulation in such neurons adapt intrinsically to neurodegeneration, to possibly neuroprotect. This is the first report on the extent and pattern of galanin expression in cholinergic neurons across distinct PPN subregions in both the intact rat CNS and lactacystin-lesioned rats. The findings pave the way for future work to target galanin signaling in the PPN, to determine the extent to which upregulated galanin expression could offer a viable treatment strategy for ameliorating PD symptoms associated with cholinergic degeneration.

Entities:  

Keywords:  Cholinergic co-expression; Galanin; Lactacystin; Parkinson’s disease; Pedunculopontine nucleus

Mesh:

Substances:

Year:  2017        PMID: 29218504     DOI: 10.1007/s12640-017-9846-2

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  70 in total

1.  Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.

Authors:  Ian F Harrison; William R Crum; Anthony C Vernon; David T Dexter
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

2.  Single cell activity patterns of pedunculopontine tegmentum neurons across the sleep-wake cycle in the freely moving rats.

Authors:  Subimal Datta; Donald F Siwek
Journal:  J Neurosci Res       Date:  2002-11-15       Impact factor: 4.164

Review 3.  Co-existence of galanin and acetylcholine: is galanin involved in memory processes and dementia?

Authors:  J N Crawley; G L Wenk
Journal:  Trends Neurosci       Date:  1989-08       Impact factor: 13.837

4.  Evidence for a possible glycinergic inhibitory neurotransmission in the midbrain and rostral pons of the rat studied by gephyrin.

Authors:  E M Mineff; A Popratiloff; R Romansky; V Kazakos; V Kaimaktschieff; K G Usunoff; W Ovtscharoff; E Marani
Journal:  Arch Physiol Biochem       Date:  1998-07       Impact factor: 4.076

5.  Investigation the mechanism of the apoptosis induced by lactacystin in gastric cancer cells.

Authors:  Yinghua Li; Haifeng Gao; Yan Wang; Chaoyang Dai
Journal:  Tumour Biol       Date:  2014-12-27

Review 6.  Neuropeptides in learning and memory processes with focus on galanin.

Authors:  Sven Ove Ogren; Eugenia Kuteeva; Elin Elvander-Tottie; Tomas Hökfelt
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

7.  Glycine-immunoreactive neurones in the cat brain stem reticular formation.

Authors:  P Fort; P H Luppi; M Jouvet
Journal:  Neuroreport       Date:  1993-09       Impact factor: 1.837

8.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy.

Authors:  E C Hirsch; A M Graybiel; C Duyckaerts; F Javoy-Agid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 9.  Galanin: a biologically active peptide.

Authors:  Maria E Vrontakis
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2002-12

10.  Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.

Authors:  Caroline R Elliott-Hunt; Fiona E Holmes; Dean M Hartley; Sylvia Perez; Elliott J Mufson; David Wynick
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

View more
  3 in total

1.  Characterization of functional subgroups among genetically identified cholinergic neurons in the pedunculopontine nucleus.

Authors:  B Baksa; A Kovács; T Bayasgalan; P Szentesi; Á Kőszeghy; P Szücs; Balázs Pál
Journal:  Cell Mol Life Sci       Date:  2019-02-08       Impact factor: 9.261

Review 2.  Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson's Disease.

Authors:  Nicole Elaine Chambers; Kathryn Lanza; Christopher Bishop
Journal:  Front Pharmacol       Date:  2020-01-15       Impact factor: 5.810

3.  DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats.

Authors:  Puneet K Sharma; Lisa Wells; Gaia Rizzo; Joanna L Elson; Jan Passchier; Eugenii A Rabiner; Roger N Gunn; David T Dexter; Ilse S Pienaar
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.